Targeting the myocardium in hypertensive left ventricular hypertrophy

References

• Myers MG, Godwin M, Dawes M, et al. Measurement of blood pressure in the office: recognizing the problem and proposing the solution. Hypertension. 2010;55(2):195–200.
   PubMed Web of Science ®Google Scholar
• Campbell NR, McKay DW, Chockalingam A, et al. Errors in assessment of blood pressure: blood pressure measuring technique. Can J Public Health. 1994;85(Suppl 2):S18–21.
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens. 2013;31:1281–1357.
   PubMed Web of Science ®Google Scholar
• James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults. JAMA. 2014;311(5):507.
   PubMed Web of Science ®Google Scholar
• Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens. 2014;16(1):14–26.
   PubMed Web of Science ®Google Scholar
• The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–2116.
   PubMed Web of Science ®Google Scholar
• Chin C, Vassiliou V, Jenkins WS, et al. Markers of left ventricular decompensation in aortic stenosis. Expert Rev Cardiovasc Ther. 2014;12:901–912.
   PubMedGoogle Scholar
• Hein S, Arnon E, Kostin S, et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart structural deterioration and compensatory mechanisms. Circulation. 2003;107(7):984–991.
   PubMed Web of Science ®Google Scholar
• Mewton N, Liu CY, Croisille P, et al. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011;57(8):891–903.
   PubMed Web of Science ®Google Scholar
• Weidemann F, Herrmann S, Störk S, et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation. 2009;120(7):577–584.
   PubMed Web of Science ®Google Scholar
• De Marco M, Gerdts E, Mancusi C, et al. Influence of left ventricular stroke volume on incident heart failure in a population with preserved ejection fraction (from the strong heart study). Am J Cardiol. 2017;119(7):1047–1052.
   PubMed Web of Science ®Google Scholar
• Briasoulis A, Mallikethi-Reddy S, Palla M, et al. Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis. Heart. 2015;101:1–6.
   PubMed Web of Science ®Google Scholar
• Gulati A, Jabbour A, Ismail TF, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013;309(9):896–908.
   PubMed Web of Science ®Google Scholar
• Chin C, Everett RJ, Kwiecinski J, et al. Myocardial fibrosis and cardiac decompensation in aortic stenosis. JACC Cardiovasc Imaging. 2016 Dec 8. doi:10.1016/j.jcmg.2016.10.007. [Epub ahead of print].
   Google Scholar
• Cuspidi C, Quarti F, Dell’Oro R, et al. Long-term changes in left ventricular mass echocardiographic findings from a general population. J Hypertens. 2017Jun 24. doi:10.1097/HJH.0000000000001453. [Epub ahead of print].
   Google Scholar
• Sekizuka H, Osada N, Akashi YJ. Impact of obstructive sleep apnea and hypertension on left ventricular hypertrophy in Japanese patients. Hypertens Res. 2016;40(5):477–482.
   PubMed Web of Science ®Google Scholar
• Sukhija R, Aronow WS, Sandhu R, et al. Prevalence of left ventricular hypertrophy in persons with and without obstructive sleep apnea. Cardiology in Review. 2006;14(4):170–172.
   PubMedGoogle Scholar
• Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;28(1):1–e14.
   Web of Science ®Google Scholar
• Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114(5):345–352.
   PubMed Web of Science ®Google Scholar
• Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham heart study. J Am Coll Cardiol. 1995;25(4):879–884.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Schillaci G, Borgioni C, et al. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. J Am Coll Cardiol. 1995;25(4):871–878.
   PubMed Web of Science ®Google Scholar
• Ghali JK, Liao Y, Cooper RS. Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol. 1998;31(7):1635–1640.
   PubMed Web of Science ®Google Scholar
• Paoletti E, De Nicola L, Gabbai FB, et al. Associations of left ventricular hypertrophy and geometry with adverse outcomes in patients with CKD and hypertension. Clin J Am Soc Nephrol. 2016;11(2):271–279.
   PubMed Web of Science ®Google Scholar
• Khouri MG, Peshock RM, Ayers CR, et al. A 4-tiered classification of left ventricular hypertrophy based on left ventricular geometry: the Dallas heart study. Circ Imaging. 2010;3(2):164–171.
   PubMed Web of Science ®Google Scholar
• Bang CN, Gerdts E, Aurigemma GP, et al. Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients. Circ Cardiovasc Imaging. 2014;7(3):422–429.
   PubMed Web of Science ®Google Scholar
• Chin C, Semple S, Malley T, et al. Optimization and comparison of myocardial T1 techniques at 3T in patients with aortic stenosis. Eur Heart J Cardiovasc Imaging. 2014;15(5):556–565.
   PubMed Web of Science ®Google Scholar
• Schillaci G, Verdecchia P, Porcellati C, et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension. 2000;35(2):580–586.
   PubMed Web of Science ®Google Scholar
• Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001;141(3):334–341.
   PubMed Web of Science ®Google Scholar
• Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004;292(19):2343–2349.
   PubMed Web of Science ®Google Scholar
• Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004;292(19):2350–2356.
   PubMed Web of Science ®Google Scholar
• Devereux RB, Pickering TG, Harshfield GA, et al. Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regularly recurring stress. Circulation. 1983;68(3):470–476.
   PubMed Web of Science ®Google Scholar
• Missault LH, De Buyzere ML, De Bacquer DD, et al. Relationship between left ventricular mass and blood pressure in treated hypertension. J Hum Hypertens. 2002;16(1):61–66.
   PubMed Web of Science ®Google Scholar
• Lønnebakken MT, Izzo R, Mancusi C, et al. Left ventricular hypertrophy regression during antihypertensive treatment in an outpatient clinic (the Campania Salute Network). J Am Heart Assoc. 2017;6(3):e004152–16.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–1847.
   PubMed Web of Science ®Google Scholar
• Desai AS. Heart failure with preserved ejection fraction: time for a new approach? J Am Coll Cardiol. 2013;62(4):272–274.
   PubMed Web of Science ®Google Scholar
• Senni M, Paulus WJ, Gavazzi A, et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J. 2014;35(40):2797–2815.
   PubMed Web of Science ®Google Scholar
• Lam CSP, Donal E, Kraigher-Krainer E, et al. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2014;13(1):18–28.
   Web of Science ®Google Scholar
• Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102(12):1388–1393.
   PubMed Web of Science ®Google Scholar
• Díez J, Querejeta R, López B, et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 2002;105(21):2512–2517.
   PubMed Web of Science ®Google Scholar
• Lueder Von TG, Wang BH, Kompa AR, et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail. 2015;8(1):71–78.
   PubMed Web of Science ®Google Scholar
• Roubille F, Busseuil D, Merlet N, et al. Investigational drugs targeting cardiac fibrosis. Expert Rev Cardiovasc Ther. 2014;12(1):111–125.
   PubMedGoogle Scholar